CNN

AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study results with masitinib in severe ...

The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma to be delivered as a late ...
Business Insider

AB Science announces the postponement of its annual general shareholders’ meeting

AB Science SA (Euronext - FR0010557264 - AB) today announces the postponement of its annual general shareholders’ meeting. In the exceptional context of the Covid-19 pandemic and in accordance with ...
Yahoo Finance

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
Morningstar

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

AB Science SA (Euronext - FR0010557264 - AB) today announced the approval of the third of four stages of the Phase I/II study (AB18001) with the compound AB8939 in adult patients with ...
Yahoo UK & Ireland

AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces today that the ...
Business Insider

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML ...
FOX8 Cleveland

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib ...
Yahoo Finance

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform bioRxiv. This article is entitled ‘Identification of AB8939, a novel synthetic ...
manilatimes

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management ...